INmune Bio (NASDAQ:INMB - Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect INmune Bio to post earnings of ($0.54) per share for the quarter.
INmune Bio Stock Down 0.2 %
Shares of INMB traded down $0.02 during mid-day trading on Friday, reaching $8.12. 218,012 shares of the stock traded hands, compared to its average volume of 239,226. The firm has a market cap of $215.92 million, a price-to-earnings ratio of -3.72 and a beta of 1.93. The stock has a fifty day simple moving average of $8.25 and a 200 day simple moving average of $6.32. INmune Bio has a 12-month low of $4.32 and a 12-month high of $12.72.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on INMB. Scotiabank lifted their price objective on shares of INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a research note on Tuesday, February 11th. Rodman & Renshaw began coverage on shares of INmune Bio in a research report on Tuesday, January 28th. They set a "buy" rating and a $23.00 price target for the company. Maxim Group raised their price target on shares of INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Finally, RODMAN&RENSHAW raised shares of INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $22.80.
Check Out Our Latest Stock Analysis on INmune Bio
About INmune Bio
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Recommended Stories
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
